Prolongation of renal allograft survival by anergic cells: Advantages and limitations

Clinical Transplantation

Volumn 24, Issue SUPPL. 22, 2010, Pages 6-10

  Bashuda, Hisashi ^a   Shimizu, Akira ^b   Uchiyama, Masateru ^a   Okumura, Ko ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Anergic cells; Chronic rejection; Glomerulopathy; Regulatory cells

Indexed keywords

ABATACEPT; ALLOANTIGEN; BELATACEPT; CD40 LIGAND MONOCLONAL ANTIBODY; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; MONOCLONAL ANTIBODY; THYMOCYTE ANTIBODY;

ACUTE KIDNEY FAILURE; ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOSCLEROSIS; BLEEDING; CAUSE OF DEATH; CHRONIC GRAFT REJECTION; CLONAL ANERGY; COCULTURE; GRAFT SURVIVAL; HUMAN; HYDRONEPHROSIS; IMMUNOLOGICAL TOLERANCE; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY FIBROSIS; KIDNEY GRAFT REJECTION; NONHUMAN; PRIMATE; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME; URETER OBSTRUCTION; ALLOTRANSPLANTATION; ANIMAL; IMMUNOLOGY; KIDNEY TRANSPLANTATION; PHYSIOLOGY; T LYMPHOCYTE; TRANSPLANTATION;

ANIMALS; CLONAL ANERGY; GRAFT SURVIVAL; HUMANS; IMMUNE TOLERANCE; KIDNEY TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 77954507826     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01269.x     Document Type: Review

References (17)

1. Kirk AD, Harlan DM, Armstrong NN. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997, 94:8789.
2. Pearson TC, Trambley J, Odom K. Anti-CD40 therapy extends renal allograft survival in rhesus macaques. Transplantation 2002, 74:933.
3. Ossevoort MA, Ringers J, Kuhn E-M. Prevention of renal allograft rejection in primates by blocking the B7/CD28 pathway. Transplantation 1999, 68:1010.
4. Kirk AD, Burkly LC, Batty DS. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999, 5:686.
5. Larsen CP, Pearson TC, Adams AB. Rational Development of LA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immuosuppressive properties. Am J Transplant 2005, 5:443.
6. Bashuda H, Kimikawa M, Seino K. Renal allograft rejection is prevented by adoptive transfer of anergic T cells in nonhuman primates. J Clin Invest 2005, 115:1896.
7. Lombardi G, Sidhu S, Batchelor R, Lechler R. Anergic T cells as suppressor cells in vitro. Science 1994, 264:1587.
8. Chai JG, Bartok I, Chandler O. Anergic T cells act as suppressor cells in vitro and in vivo. Eur J Immunol 1999, 29:686.
9. Luo ZJ, Gotoh M, Grochowiecki T. Anergic T cells generated in vitro suppress rejection response to islet allografts. Transplantation 2000, 69:2144.
10. Taylor PA, Noelle RJ, Blazar BR. CD4+CD25+ Immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J Exp Med 2001, 193:1311.
11. Sakaguchi S, Sakaguchi N, Shimizu J. Immunologic tolerance maintained by CD25+CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001, 182:18.
12. Kawai T, Cosimi B, Spitzer TR. HLA-Mismatched Renal Transplantation without Maintenance Immunosuppression. N Engl J Med 2008, 358:353.
13. Scandling J, Busque S, Dejbakhsh-Jones S. Tolerance and Chimerism after Renal and Hematopoietic-Cell Transplantation. N Engl J Med 2008, 358:362.
14. Gould DS, Auchincloss H. Direct and indirect recognition: the role of MHC antigens in graft rejection. Immunol Today 1999, 20:77.
15. Smith RN, Kawai T, Boskovic S. Four stages and lack of stable accommodation in chronic alloantibody-mediated renal allograft rejection in cynomolgus monkeys. Am J Transplant 2008, 8:1662.
16. Gloor JM, Sethi S, Stegall MD. Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant 2007, 7:2124.
17. Solez K, Colvin RB, Racusen LC. Banff 07 classification of renal allograft pathology: update and future directions. Am J Transplant 2008, 8:753.